Bosh sahifaTWST • NASDAQ
add
Twist Bioscience Corp
43,34 $
Seans yopilganidan keyin:(0,00%)0,00
43,34 $
Yopilgan:4-okt, 16:02:11 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
42,79 $
Kunlik diapazon
43,17 $ - 44,54 $
Yillik diapazon
14,43 $ - 60,90 $
Bozor kapitalizatsiyasi
2,54 mlrd USD
Oʻrtacha hajm
745,63 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 81,46 mln | 27,81% |
Joriy xarajat | 79,26 mln | 12,29% |
Sof foyda | -85,57 mln | -49,09% |
Sof foyda marjasi | -105,04 | -16,65% |
Har bir ulushga tushum | -0,70 | 31,23% |
EBITDA | -35,69 mln | 11,22% |
Amaldagi soliq stavkasi | -0,22% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 289,42 mln | -18,96% |
Jami aktivlari | 638,12 mln | -21,25% |
Jami passivlari | 146,98 mln | -3,80% |
Umumiy kapital | 491,14 mln | — |
Tarqatilgan aksiyalar | 58,59 mln | — |
Narxi/balansdagi bahosi | 5,10 | — |
Aktivlardan daromad | -16,40% | — |
Kapitaldan daromad | -17,91% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -85,57 mln | -49,09% |
Operatsiyalardan naqd pul | -6,38 mln | 72,76% |
Sarmoyadan naqd pul | -711,00 ming | -103,81% |
Moliyadan naqd pul | 2,91 mln | 539,94% |
Naqd pulning sof oʻzgarishi | -4,18 mln | 26,98% |
Boʻsh pul | 6,02 mln | 464,11% |
Haqida
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Tashkil etilgan
2013
Xodimlar soni
919
